uterine corpus cancer: A uterine cancer that is located_in the uterine corpus.
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
557745 |
1. Apply sex-specific ruleNone |
557745 |
2. Check conditionsNone |
557745 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
176 |
4. Check minimum number of eventsNone |
176 |
5. Include endpointsNone |
176 |
6. Filter based on genotype QC (FinnGen only) |
163 |
Control definitions (FinnGen only)
Controls for this endpoint are individuals that are not cases.
Extra metadata
- Level in the ICD hierarchy
- 3
- First used in FinnGen datafreeze
- DF2
- Parent code in ICD-10
- D10
- Name in latin
- Neoplasma benignum hypopharyngis
Similar endpoints
↥List of similar endpoints to
Benign neoplasm: Hypopharynx
based on the number of shared cases.
Similar with more cases:
- Benign neoplasm of mouth and pharynx
- Benign neoplasms
- Neoplasms
- Any operation in hilmo
- Any prescribed medicine buy
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 787 | 363 | 414 |
| Only index persons | 644 | 303 | 341 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.01 | 0.01 | 0.01 |
| Only index persons | 0.01 | 0.01 | 0.01 |
| Median age at first event (years) | |||
| Whole population | 59.62 | 57.19 | 61.60 |
| Only index persons | 59.07 | 56.24 | 61.58 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 163 | 66 | 97 |
| Unadjusted period prevalence (%) | 0.04 | 0.02 | 0.04 |
| Median age at first event (years) | 58.54 | 49.68 | 64.57 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 167
- Matched controls
- 1670
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
D10.7
ICD-10 Finland
Benign neoplasm: Hypopharynx
+∞
191.6
145
*
UJC01
NOMESCO Finland
Scopy of lower throat
95.5
113.9
61
10
JDB10
NOMESCO Finland
Percutaneous gastrostomy
50.4
30.4
36
9
504
Kela drug reimbursment
Conditions requiring daily forced enteral nutrition
30.2
27.1
36
15
130
Kela drug reimbursment
Malignant tumour
5.7
21.2
49
114
WF002
NOMESCO Finland
Radical radiotherapy
6.9
20.5
36
64
UDQ12
NOMESCO Finland
Flexible laryngoscopy
7.1
20.1
34
58
DQB10
NOMESCO Finland
Endoscopic excision of lesion of larynx
50.3
18.7
22
5
2108A
ICD-9 Finland
Benign neoplasm of lip, oral cavity and pharynx, Hypopharynx
+∞
18.0
17
*
R2130
NOMESCO Finland
Counselling and guidance which enhance independent living
5.5
17.4
39
87
D14.1
ICD-10 Finland
Benign neoplasm: Larynx
100.3
16.9
18
*
C13.8
ICD-10 Finland
Malignant neoplasm: Overlapping lesion of hypopharynx
188.0
16.8
17
*
R07.0
ICD-10 Finland
Pain in throat
6.2
14.5
27
50
WX408
NOMESCO Finland
General anesthesy, balanced
3.5
13.6
70
286
UDQ22
NOMESCO Finland
Microlaryngoscopy
22.2
12.8
18
9
D38.0
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Larynx
40.9
12.4
15
*
DQA10
NOMESCO Finland
Biopsy of larynx
70.0
11.8
13
*
EN1AD
NOMESCO Finland
CT examination of mouth and soft tissues of neck
70.0
11.8
13
*
GBB00
NOMESCO Finland
Tracheostomy
21.9
11.4
16
8
ZXE00
NOMESCO Finland
One hour or less
3.0
11.1
92
484
YA1BD
NOMESCO Finland
Extensive CT examination of head and neck for dose design of radiotherapy
46.7
11.1
13
*
UDH02
NOMESCO Finland
Rhinopharyngoscopy
5.1
10.9
25
56
EN1BD
NOMESCO Finland
Very extensive CT examination of mouth and soft tissues of neck
23.4
10.9
15
7
ENA10
NOMESCO Finland
Biopsy of pharynx
64.2
10.8
12
*
8070/3-C13.9
ICD-O-3
Squamous cell carcinoma, NOS, of hypopharynx, NOS
+∞
10.5
10
*
R4190
NOMESCO Finland
Nutritional therapy
9.4
10.4
21
25
R13
ICD-10 Finland
Dysphagia
4.2
10.2
30
82
ZXD10
NOMESCO Finland
Scheduled procedure
2.9
10.2
84
436
EP1DG
NOMESCO Finland
Very extensive examination of soft tissue of neck with high intesity magnet
32.1
9.5
12
*
C12
ICD-10 Finland
Malignant neoplasm of piriform sinus
+∞
9.5
9
*
EP1AE
NOMESCO Finland
Neck ultrasound examination
4.8
9.2
22
51
WZC10
NOMESCO Finland
Written specialist consultation based on a referral from a dentist or a physician
5.4
9.1
19
39
ZXC10
NOMESCO Finland
Use of laser
9.5
9.1
18
21
WX402
NOMESCO Finland
General anaesthesia
2.9
9.0
56
247
YA1VG
NOMESCO Finland
MRI examination of head and neck with high intesity magnet for dose design of radiotherapy
94.6
8.5
9
*
A03FA01
ATC
metoclopramide; systemic, rectal
2.8
8.3
56
257
UJC02
NOMESCO Finland
Rigid oesophagoscopy
18.3
8.2
12
7
K04.5
ICD-10 Finland
Chronic apical periodontitis
2.6
7.9
64
321
GD1AD
NOMESCO Finland
Thorax CT examination
4.2
7.8
22
58
UDQ02
NOMESCO Finland
Direct laryngoscopy
19.5
7.7
11
6
C13.9
ICD-10 Finland
Malignant neoplasm: Hypopharynx, unspecified
83.7
7.5
8
*
N02AA05
ATC
oxycodone; systemic
2.7
7.4
51
235
WB103
NOMESCO Finland
Simple adjuvant cytostatic therapy
6.9
7.2
17
27
EP1CG
NOMESCO Finland
Extensive MRI examination of soft tissue of neck with high intesity magnet
14.6
7.0
11
8
Z50.8
ICD-10 Finland
Care involving use of other rehabilitation procedures
3.9
7.0
22
63
A04AA01
ATC
ondansetron; systemic, rectal
3.5
6.9
26
84
R4110
NOMESCO Finland
Physiotherapy
2.5
6.9
63
330
A02BC05
ATC
esomeprazole; systemic
2.3
6.8
84
504
UJC12
NOMESCO Finland
Flexible oesophagoscopy
23.6
6.7
9
*
B97.7
ICD-10 Finland
Papillomavirus as the cause of diseases classified to other chapters
72.5
6.5
7
*
C01
ICD-10 Finland
Malignant neoplasm of base of tongue
72.5
6.5
7
*
N02AB03
ATC
fentanyl; nasal, sublingual, transdermal
4.3
6.3
17
43
WX700
NOMESCO Finland
Respiratory and circulatory monitoring
2.7
6.3
38
162
ENB00
NOMESCO Finland
Excision or exploration of lesion of pharynx
+∞
6.3
6
*
C13.1
ICD-10 Finland
Malignant neoplasm: Aryepiglottic fold, hypopharyngeal aspect
+∞
6.3
6
*
WX404
NOMESCO Finland
Intravenous generell anesthesy
2.6
6.3
45
210
ZXA05
NOMESCO Finland
Left side
2.4
6.2
54
276
EB1HA
NOMESCO Finland
Panorama tomography of teeth and jaws or similar X-ray examination
2.3
6.2
78
467
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
62
274
3.01
10.09
2.9
3.0
1.07
0.88
e6/l
0.20
29
148
58
258
2.91
9.21
3.1
3.2
2.06
1.78
e6/l
0.12
25
134
82
445
2.66
8.78
4.0
3.2
0.43
0.52
e6/l
0.12
61
334
126
866
2.85
8.05
14.8
10.9
4.28
4.11
e9/l
0.38
113
748
107
680
2.60
8.01
7.3
4.9
33.76
35.45
g/l
2.31
100
646
114
753
2.62
7.77
11.3
7.7
1.20
1.21
mmol/l
0.88
104
665
26
87
3.36
6.57
1.9
1.9
—
—
—
0
0
64
348
2.36
6.40
2.8
2.5
—
—
—
0
0
85
522
2.28
6.37
5.0
3.6
2.33
2.35
mmol/l
0.74
79
475
39
182
2.49
5.36
4.0
5.4
242.90
256.07
u/l
0.17
39
177
97
678
2.03
4.73
3.3
2.9
—
—
estimate
—
0
0
62
375
2.04
4.48
2.0
2.0
2.50
2.89
mg/l
0.92
53
331
9
12
7.85
4.41
1.3
1.3
—
—
—
0
0
55
321
2.06
4.36
1.6
1.9
1.17
1.53
mg/l
0.61
50
256
(3020427) Coagulation factor X inhibitor [Units/volume] in Platelet poor plasma by Coagulation assay
14
41
3.64
4.29
2.3
2.5
0.25
0.40
iu/ml
—
9
23
47
261
2.11
4.23
2.3
1.9
—
—
—
0
0
52
301
2.06
4.19
3.7
4.1
50.04
281.73
ng/l
1.57
43
240
131
1047
2.17
4.13
5.9
4.2
14.78
14.85
pmol/l
0.12
125
944
93
662
1.91
4.08
2.3
2.1
91.00
92.36
pmol/l
0.08
48
358
115
894
1.92
3.69
8.1
5.2
6.95
6.69
mmol/l
0.53
110
855
12
30
4.23
3.68
1.4
1.3
—
—
—
0
0
108
826
1.87
3.61
11.0
7.5
10.15
11.75
umol/l
1.70
103
788
14
47
3.16
3.50
1.8
2.8
199.86
204.43
%
0.07
14
47
148
1273
2.43
3.42
7.1
5.2
2.01
1.98
mu/l
0.08
142
1159
27
130
2.28
3.41
3.6
2.5
70.45
63.57
ml/min/173m2
0.25
11
53
14
50
2.96
3.17
1.5
2.4
99.86
87.36
%
1.16
14
50
35
193
2.03
3.16
2.1
1.9
—
—
—
0
0
62
417
1.77
3.04
3.4
3.0
343.59
354.18
umol/l
0.31
56
358
19
83
2.45
2.97
1.6
1.3
—
—
—
0
0
35
199
1.96
2.89
2.1
1.8
—
—
—
0
0
27
143
2.06
2.70
3.7
2.1
335.96
381.70
nmol/l
0.78
27
132
9
26
3.60
2.52
1.4
1.1
—
—
—
0
0
5
8
6.40
2.39
1.2
2.4
—
—
—
0
0
5
8
6.40
2.39
1.2
2.4
—
—
—
0
0
37
230
1.78
2.31
10.1
7.8
104.03
104.16
mmol/l
0.05
37
230
36
224
1.77
2.24
1.3
1.3
65.45
13.38
u/ml
0.88
11
91
6
14
4.40
2.17
1.2
1.6
—
—
—
0
0
114
954
1.61
2.16
4.2
3.6
68.24
53.29
u/l
0.74
105
909
154
1403
2.25
2.16
31.4
17.3
29.65
24.64
mg/l
1.19
139
1168
62
452
1.59
2.12
1.8
1.7
19.15
20.85
nmol/l
0.56
57
375
30
181
1.80
2.06
12.2
9.1
1.34
0.59
mmol/l
0.50
24
155
19
100
2.02
1.95
12.8
9.3
24.89
24.41
mmol/l
0.23
19
100
34
217
1.71
1.94
1.5
1.5
—
—
—
0
0
82
649
1.52
1.90
3.6
2.8
159.42
137.14
ug/l
0.45
77
603
65
491
1.53
1.86
5.7
2.6
50.22
76.42
u/l
1.34
59
459
100
829
1.51
1.84
2.7
2.8
—
—
—
0
0
37
248
1.63
1.75
1.4
1.3
51.89
36.17
iu/ml
0.23
11
74
5
13
3.93
1.72
1.0
1.1
—
—
—
0
0
10
40
2.59
1.70
1.3
1.2
—
—
—
0
0
6
20
3.07
1.59
1.3
1.1
—
—
—
0
0
11
51
2.24
1.54
2.5
2.1
—
—
—
0
0
36
249
1.57
1.50
1.7
1.6
1014.46
1223.12
nmol/l
0.65
22
192
9
38
2.44
1.48
1.8
1.4
—
—
—
0
0
18
103
1.84
1.48
1.4
1.5
—
—
—
0
0
5
16
3.19
1.45
1.2
1.3
—
—
—
0
0
10
46
2.25
1.43
2.0
1.8
—
—
—
0
0
22
136
1.71
1.41
2.9
2.6
0.17
0.23
e6/l
0.29
22
130
7
29
2.47
1.41
1.3
1.5
—
—
—
0
0
155
1454
1.92
1.37
34.0
20.2
138.78
139.74
mmol/l
3.96
155
1434
155
1458
1.88
1.29
34.5
20.4
3.98
4.00
mmol/l
0.30
155
1437
8
36
2.28
1.26
1.4
1.4
—
—
—
0
0
25
167
1.58
1.21
6.4
3.5
—
—
—
0
0
94
810
1.37
1.18
5.4
3.8
0.24
0.00
estimate
0.63
21
163
14
81
1.80
1.13
1.1
1.2
403.40
86.50
u/ml
—
5
26
93
804
1.35
1.12
5.5
3.8
0.04
9.07
estimate
0.49
23
179
92
795
1.35
1.11
5.4
3.8
0.00
0.00
estimate
-0.00
22
173
129
1177
1.42
1.10
35.6
21.7
13.95
13.68
%
1.42
129
1169
5
23
2.21
0.98
1.2
1.1
—
—
—
0
0
72
608
1.32
0.98
4.7
4.1
30.73
46.49
ng/l
0.72
53
452
9
50
1.84
0.98
1.7
1.5
—
—
—
0
0
22
152
1.52
0.94
13.2
7.1
11.93
9.75
mmol/l
0.75
22
147
156
1490
1.71
0.92
37.5
22.7
83.37
81.68
umol/l
0.15
156
1477
6
28
2.18
0.92
1.0
1.2
—
—
—
0
0
8
44
1.86
0.87
1.3
1.3
—
—
—
0
0
63
531
1.30
0.85
7.2
4.0
23.39
12.19
mg/mmol
0.43
47
338
12
74
1.67
0.80
2.7
3.3
3.77
4.53
pmol/l
2.63
12
63
6
34
1.79
0.77
1.2
1.3
—
—
—
0
0
6
34
1.79
0.77
1.0
1.1
—
2.34
—
0
5
7
38
1.88
0.74
1.6
1.4
—
—
—
0
0
145
1377
1.40
0.73
30.4
17.2
81.18
79.10
ml/min/173m2
0.57
139
1285
9
57
1.61
0.72
1.8
2.6
—
—
—
0
0
59
504
1.26
0.70
2.8
3.5
2120.04
1352.65
ng/l
0.49
52
424
16
112
1.47
0.66
1.7
2.0
—
—
—
0
0
5
29
1.75
0.64
1.8
1.4
—
—
—
0
0
5
29
1.75
0.64
1.8
1.4
—
—
—
0
0
142
1351
1.34
0.64
8.8
6.8
42.62
39.68
mmol/mol
1.96
136
1269
13
88
1.52
0.62
2.6
4.5
25.55
24.01
mmol/l
0.51
13
88
0
20
0.00
0.61
0.0
1.3
—
—
—
0
0
6
35
1.74
0.58
2.0
2.3
—
—
—
0
0
6
36
1.69
0.57
1.0
1.2
1.00
0.91
g/l
—
6
36
6
38
1.60
0.55
1.2
1.4
—
—
—
0
0
6
38
1.60
0.55
1.3
1.9
—
—
—
0
0
36
303
1.24
0.49
1.6
1.8
487.41
44828012.92
pmol/l
0.50
29
261
7
47
1.51
0.48
1.7
1.5
—
—
—
0
0
156
1517
1.43
0.48
44.7
26.5
38.59
40.74
%
3.44
156
1508
156
1517
1.43
0.48
42.9
25.8
91.75
91.53
fl
0.25
156
1508
156
1517
1.43
0.48
43.6
26.1
131.11
136.42
g/l
3.43
156
1509
5
31
1.63
0.43
9.0
3.2
7.66
9.97
pmol/l
—
5
31
5
34
1.48
0.40
1.0
1.1
1.52
1.52
g/l
—
5
34
18
142
1.30
0.40
4.4
3.0
4.32
4.39
kpa
0.07
18
137
5
35
1.44
0.39
1.6
1.4
—
—
—
0
0
47
416
1.18
0.39
2.9
3.3
0.98
0.80
ug/l
0.34
35
271
146
1415
1.25
0.38
6.4
6.3
2.58
2.67
mmol/l
0.64
140
1312
6
41
1.48
0.36
2.0
2.2
—
—
—
0
0
12
91
1.34
0.35
3.9
2.4
0.78
0.57
%
1.06
12
91
6
44
1.38
0.35
1.5
1.4
—
—
—
0
0
138
1334
1.20
0.34
4.6
4.5
1.28
1.28
mmol/l
0.05
129
1228
6
45
1.35
0.34
2.2
1.4
—
—
—
0
0
12
93
1.31
0.31
3.9
2.5
2.37
1.25
%
0.87
12
93
49
444
1.15
0.30
6.2
3.8
0.00
0.01
estimate
0.50
18
161
42
462
0.88
0.26
5.8
3.5
0.00
0.00
estimate
-0.00
19
139
5
41
1.23
0.22
1.0
1.3
—
—
—
0
0
0
11
0.00
0.21
0.0
1.8
—
—
—
0
0
0
12
0.00
0.21
0.0
2.6
—
13.73
—
0
12
0
14
0.00
0.20
0.0
1.1
—
162.01
—
0
14
141
1384
1.12
0.16
5.4
5.4
1.36
1.44
mmol/l
1.55
135
1280
141
1388
1.10
0.13
5.5
5.5
4.42
4.57
mmol/l
0.95
135
1294
59
614
0.94
0.11
6.2
3.8
0.00
0.03
estimate
0.68
19
148
18
164
1.11
0.10
1.4
1.6
—
—
—
0
0
35
331
1.07
0.10
5.3
4.0
1.02
1.02
kg/l
0.03
27
222
19
176
1.09
0.08
9.3
7.4
—
—
—
0
0
14
130
1.08
0.04
1.2
1.4
—
—
—
0
0
138
1369
1.05
0.04
6.3
5.3
6.26
6.03
mmol/l
0.81
132
1256
11
102
1.08
0.03
1.9
2.0
—
—
—
0
0
17
171
0.99
0.00
4.4
5.3
28.00
31.94
%
1.38
12
104
34
336
1.01
0.00
1.3
1.3
0.97
1.15
u/ml
—
7
92
69
694
0.99
0.00
4.7
5.6
2.04
2.78
ug/l
0.67
63
631
0
7
0.00
0.00
0.0
1.1
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
0.00
0.0
1.8
—
—
—
0
0
0
7
0.00
0.00
0.0
1.7
—
—
—
0
0
0
7
0.00
0.00
0.0
1.1
—
—
—
0
0
0
5
0.00
0.00
0.0
3.6
—
67.04
—
0
5
0
7
0.00
0.00
0.0
1.1
—
—
—
0
0
0
5
0.00
0.00
0.0
1.2
—
9.72
—
0
5
0
7
0.00
0.00
0.0
1.7
—
—
—
0
0
0
5
0.00
0.00
0.0
1.4
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
-0.00
0.0
4.8
—
10.21
—
0
8
0
8
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
10.14
—
0
6
7
69
1.02
-0.00
1.1
1.0
—
—
—
0
0
6
60
1.00
-0.00
1.5
1.3
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.4
—
58.02
—
0
8
0
6
0.00
-0.00
0.0
2.3
—
43.15
—
0
6
0
8
0.00
-0.00
0.0
4.8
—
4.61
—
0
8
56
560
1.00
-0.00
4.2
4.8
27.08
21.66
%
1.05
29
283
Mortality – FinRegistry
↥Association
Association between endpoint CD2_BENIGN_HYPOPHARYNX and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| CD2_BENIGN_HYPOPHARYNX | 1.911 [1.25, 2.93] | 0.003 |
| Birth year | 0.988 [0.98, 1.0] | 0.006 |
During the follow-up period (1.1.1998 — 31.12.2019), 51 out of 188 females with CD2_BENIGN_HYPOPHARYNX died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| CD2_BENIGN_HYPOPHARYNX | 2.396 [1.56, 3.67] | < 0.001 |
| Birth year | 0.991 [0.98, 1.0] | 0.073 |
During the follow-up period (1.1.1998 — 31.12.2019), 104 out of 275 males with CD2_BENIGN_HYPOPHARYNX died.
Mortality risk
Mortality risk for people of age
years, who have CD2_BENIGN_HYPOPHARYNX.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.142% | 0.394% |
| 5 | 0.951% | 2.999% |
| 10 | 2.338% | 8.24% |
| 15 | 4.195% | 14.837% |
| 20 | 6.865% | 24.105% |
Relationships between endpoints
↥Index endpoint: CD2_BENIGN_HYPOPHARYNX – Benign neoplasm: Hypopharynx
GWS hits: 1
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data